IP Library Granted Patent US 11,413,295
Granted Patent B2
US 11,413,295 · App. 16/089,477 · Granted Aug 16, 2022

Oral preparation of obeticholic acid

Inventors: Mitsuhiro Matono (Osaka, JP); Tetsuya Hayama (Osaka, JP)
Assignee: INTERCEPT PHARMACEUTICALS, INC.
A61K31/575A61K9/14A61K9/1682A61K9/20A61K9/28A61K47/10A61K47/26A61K47/32A61K47/36A61K47/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,413,295
App. No.
16/089,477
Granted
Aug 16, 2022
Kind
B2
Abstract

The present invention pertains to an oral preparation having exceptional elutability, the oral preparation containing obeticholic acid or a pharmacologically acceptable salt thereof, a water-soluble excipient, a disintegrating agent, and a water-soluble polymer binder, wherein the oral preparation is a quick-release tablet.

Claims (14)

1. An oral preparation, comprising obeticholic acid or a pharmacologically acceptable salt thereof, (i) a water-soluble excipient, wherein the water-soluble excipient is a sugar or a sugar alcohol; (ii) a disintegrating agent, wherein the disintegrating agent is selected from any one or more of a starch, sodium croscarmellose, carmellose, low-substituted hydroxypropyl cellulose, and crospovidone; and (iii) a water-soluble polymer binder, wherein the water-soluble polymer binder is a polyvinyl alcohol-based resin, wherein the preparation is a quick-release tablet.

2. The oral preparation of claim 1 , wherein the sugar or sugar alcohol is mannitol or lactose.

3. The oral preparation of claim 1 , wherein the starch is a pre-gelatinized starch.

4. The oral preparation of claim 3 , wherein the pre-gelatinized starch is a partly pre-gelatinized starch.

5. The oral preparation of claim 1 , wherein the disintegrating agent comprises two different types, (iia) a disintegrating agent A and (iib) a disintegrating agent B.

6. The oral preparation of claim 5 , wherein the disintegrating agent A is selected from a starch, sodium croscarmellose, carmellose, calcium carmellose, sodium carmellose, crospovidone, low-substituted hydroxypropyl cellulose, and sodium carboxymethyl starch, and the disintegrating agent B is any disintegrating agent other than the disintegrating agent A, selected from a starch, sodium croscarmellose, carmellose, calcium carmellose, sodium carmellose, crospovidone, low-substituted hydroxypropyl cellulose, and sodium carboxymethyl starch.

7. The oral preparation of claim 6 , wherein the disintegrating agent A is a starch.

8. The oral preparation of claim 7 , wherein the starch is a pre-gelatinized starch or partly pre-gelatinized starch.

9. The oral preparation of claim 6 , wherein the disintegrating agent A is low-substituted hydroxypropyl cellulose.

10. The oral preparation of claim 6 , wherein the disintegrating agent B is any of crospovidone, sodium croscarmellose, or sodium carboxymethyl starch.

11. The oral preparation of claim 10 , wherein the disintegrating agent B is crospovidone.

12. The oral preparation of claim 1 , wherein the polyvinyl alcohol-based resin is a polyvinyl alcohol, polyvinyl alcohol derivative, or polyvinyl alcohol copolymer.

13. The oral preparation of claim 1 , wherein the obeticholic acid or pharmacologically acceptable salt thereof is an amorphous form.

14. The oral preparation of claim 1 , wherein the obeticholic acid or pharmacologically acceptable salt thereof is obeticholic acid.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jan 4, 2024
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 066662/0210 →
CHANGE OF ADDRESS Recorded Aug 22, 2022
From: INTERCEPT PHARMACEUTICALS, INC.
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 061297/0990 →
SECURITY INTEREST Recorded Aug 18, 2021
From: INTERCEPT PHARMACEUTICALS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 057650/0772 →
Priority Claims (1)
JP JP2016-071404 · Mar 31, 2016 · national
Continuity (1)
Related Publication 20190216826A1 · Jul 18, 2019